A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficiency and Safety Profile of Insulin Aspart (NovoRapid) and Human Soluble Insulin (Novolin R) as Meal Related Insulin in a Three Times Daily Regimen With One Injection of Novolin N at Bedtime in Chinese Type 1 and 2 Diabetics.

Trial Profile

A Multi-centre, Randomised, Parallel, Open Labelled Study to Compare the Efficiency and Safety Profile of Insulin Aspart (NovoRapid) and Human Soluble Insulin (Novolin R) as Meal Related Insulin in a Three Times Daily Regimen With One Injection of Novolin N at Bedtime in Chinese Type 1 and 2 Diabetics.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Dec 2016

At a glance

  • Drugs Insulin aspart (Primary) ; Insulin
  • Indications Diabetes mellitus; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 24 May 2012 Official Title amended as reported by ClinicalTrials.gov.
    • 18 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top